CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Hu, Zhangwei; Sun, Wei; Wen, Yihui; Ma, Rong; Chen, Lin; Chen, Wenqing; Lei, Wenbin; Wang, Wen

doi:10.3389/fimmu.2022.952059

Cited by 16 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 39 ] CD69 as Potential Predictors of Responses to PD-1/PD-L1 Blockade Cancer Immunotherapy in Lung Cancer and Melanoma. [ 40 ] GZMK shows promise as a potential diagnostic marker for the early detection of rheumatoid arthritis. This is especially true for patients who test negative for anti-citrullinated protein antibodies.…”

Section: Discussionmentioning

confidence: 99%

A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review

Li,

Hu,

et al. 2024

Medicine

View full text Add to dashboard Cite

Testicular germ cell tumors (TGCT) are the most common testicular malignancies. KLRB1 is considered to influence the development and progression of a number of cancers. However, it is unclear how the KLRB1 gene functions in TGCT. First, it was determined the expression level of KLRB1 in TGCT using The Cancer Genome Atlas (TCGA) (The Cancer Genome Atlas) dataset and GTEx (Genotype-Tissue Expression) dataset. The clinical significance and biological functions of KLRB1 were explored using the TCGA dataset, and we analyzed the correlation of the KLRB1 gene with tumor immunity and infiltrating immune cells using gene set variation analysis and the TIMER database. We found that the expression level of KLRB1 was upregulated in TGCT malignant tissues with the corresponding normal tissues as controls, and KLRB1 expression correlated with clinicopathologic features of TGCT. Functional enrichment analysis suggested that KLRB1 might be involved in immune response and inflammatory response. KLRB1 was highly positively correlated with natural killer cell activation in immune response and positively correlated with tumor-infiltrating immune cells. This study demonstrated for the first time the role of KLRB1 in TGCT, which may serve as a new biomarker associated with immune infiltration and provide a potential therapeutic target for the treatment of TGCT.

show abstract

Section: Discussionmentioning

confidence: 99%

A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review

Li,

Hu,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…High-fat diet and fatty acid attack also augmented SBK1 expression. 38 Hu et al 39 found that SBK1 expression was inversely related to infiltrating immune cells. SBK1 could phosphorylate ERK and be phosphorylated by PKA in Drosophila.…”

Section: Discussionmentioning

confidence: 99%

SH3 domain‐binding kinase 1 promotes proliferation and inhibits apoptosis of cervical cancer via activating the Wnt/β‐catenin and Raf/ERK1/2 signaling pathways

Chen

Sun

Zhou

et al. 2023

Molecular Carcinogenesis

View full text Add to dashboard Cite

SH3 domain‐binding kinase 1 (SBK1), is a member of the serine/threonine protein kinases family, and was confirmed to be upregulated in cervical cancer in our previous study. Nonetheless, the role of SBK1 in regulating cancer occurrence and development is unclear. In this study, the stable SBK1‐knockdown and ‐overexpressed cell models were constructed by plasmid transfection technology. Cell viability and growth were assessed through CCK‐8, colony formation, and BrdU methods. Cell cycle and apoptosis were analyzed by flow cytometry. The JC‐1 staining assay was used to explore mitochondrial membrane potential. The scratch and Transwell assays were used to evaluate the cell metastatic ability. The nude mice models were utilized to explore the SBK1 expression affecting tumor growth in vivo. Our research indicated a high expression of SBK1 both in tissues and cells of cervical cancer. The proliferative, migratory, as well as invasive capacities of cervical cancer cells, were suppressed, and apoptosis was enhanced after SBK1 silence, whereas SBK1 upregulation led to opposite results. In addition, Wnt/β‐catenin and Raf/ERK1/2 pathways were activated by SBK1 upregulation. Furthermore, downregulation of c‐Raf or β‐catenin, reversed the proliferation promotion and apoptosis inhibition effects in SBK1‐overexpressed cells. The same results were observed with the use of the specific Raf inhibitor. SBK1 overexpression also contributed to tumor growth in vivo. Overall, SBK1 played a vital role in cervical tumorigenesis via activating the Wnt/β‐catenin and Raf/ERK1/2 pathways.

show abstract

“…In PC9 cells, Gefitinib could promote FBP1 expression and inhibit SBK1 and AURKA levels. An increasing body of evidence suggests that FBP1, SBK1 and AURKA are associated with lung cancer progression [10][11][12][13][14][15]. For instance, FBP1 was found to be downregulated in lung cancer tissues and cells.…”

Section: Discussionmentioning

confidence: 99%

A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients

Guo,

Li,

Jiang

et al. 2023

Aging

View full text Add to dashboard Cite

Purpose: Gefitinib, an anticancer drug, has been reported to potentially improve the prognosis of patients with lung adenocarcinoma (LUAD). This study aims to investigate the roles and mechanisms of Gefitinib. Methods: The effects of Gefitinib on the growth and migration of LUAD cells were assessed using various methods, including CCK-8, flow cytometry, wound healing, and Transwell assays. To analyze the function and mechanisms of the differentially expressed Gefitinib target genes (GTGs), data from the TCGA database were utilized. Kaplan-Meier survival and ROC analysis identified prognostic-related GTGs and constructed a prognostic nomogram in LUAD. Consensus clustering, COX analysis and survival analysis evaluated the relationship between GTGs and the prognosis of LUAD patients. The mechanisms of the risk model involved LUAD progression, and the relationship between the risk model and immune microenvironment were investigated. Results: Gefitinib could inhibit proliferation, migration and invasion and promote cell apoptosis. 84 DEGTGs were involved in RAS, MAPK, ERBB pathways. The DEGTGs (FBP1, SBK1, and AURKA) were the independent risk factors for dismal prognosis of LUAD patients and were used to establish risk model and nomogram. Gefitinib could promote the expression of FBP1 and inhibit the expression of SBK1 and AURKA. High-risk LUAD patients had the dismal prognosis, and the high-risk score group was significantly associated with the immune microenvironment. Conclusion: FBP1, SBK1, and AURKA are prognostic risk factors, and the risk model and nomogram of FBP1, SBK1 and AURKA are associated with dismal prognosis and immune cell infiltration, and have huge prospects for application in evaluating the prognosis in LUAD.

show abstract

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Cited by 16 publications

References 54 publications

A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review

A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review

SH3 domain‐binding kinase 1 promotes proliferation and inhibits apoptosis of cervical cancer via activating the Wnt/β‐catenin and Raf/ERK1/2 signaling pathways

A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients

Contact Info

Product

Resources

About